AWRENCE, Mass., Aug. 12, 2014 /PRNewswire/ -- NxStage Medical, Inc. (NASDAQ: NXTM), a leading manufacturer of innovative dialysis products, announced today that Allan J. Collins, M.D., a recognized worldwide leader in the field of nephrology, will join the Company as Senior Medical Advisor and head the Company's Medical Advisory Board.
Dr. Collins is a Professor of Medicine at the University of Minnesota. He is the Director of the Chronic Research Disease Group, an interdisciplinary biomedical research group committed to the investigation of chronic illnesses to improve public health, and as part of this, served as the coordinating center for the United States Renal Data System (USRDS) and its Annual Data Report from 2000 through 2014. Dr. Collins was presented the Distinguished Service Award by the National Kidney Foundation (NKF) in 2003, and served as the President of the NKF from 2006 through 2008. He has over 200 clinical publications, and is an invited lecturer worldwide. Dr. Collins continues his clinical practice with dialysis patients under his care as the Medical Director for the DaVita Coon Valley Dialysis Unit. Dr. Collins has served as a member of the NxStage® Scientific Advisory Board for the last 4 years.
"I believe fresh approaches with innovative technologies are essential to address the long intractable problems we've seen with chronic dialysis therapy, particularly cardiovascular issues and low quality of life," said Collins. "The talented NxStage team has substantially advanced home dialysis therapies to date, and will continue to do so on a broader scale with future innovations. It will be a pleasure to help advance the care of the dialysis population by advising NxStage on data-driven analytics and communications while leading a world-class team of medical advisors."
Dr. Collins will assume the leadership role from Dr. Alan Hull, who has headed the NxStage Medical Advisory Board since 2004.
"We have always actively sought the best scientific counsel in our ongoing mission to invent, improve and inspire," said Joe Turk, NxStage's President. "We thank Dr. Hull for all of his years of commitment, and we are delighted that Dr. Collins will now be collaborating so closely with NxStage going forward. NxStage, and future patients for our life-changing technologies, will benefit from the ongoing contributions of Dr. Collins' tremendous knowledge and leadership skills."
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.